ArticleJournal of clinical medicine research2025
Organ Damage and Its Associated Factors in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study.
Article in Journal of clinical medicine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Sex-based differences in clinical phenotype and damage accrual among patients with systemic lupus erythematosus in Saudi Arabia: a multicenter cross-sectional study.Clinical rheumatology · 2026Article
- Real-world treatment patterns and outcomes in moderate-to-severe SLE: findings from the Spanish SPOCS cohort.Lupus science & medicine · 2026Observational
- Clinical, serological, and targeted genetic analysis of systemic lupus erythematosus in Kazakhstan.Lupus · 2026Article
- NETosis inhibitory activity of LBW newborns' cord blood plasma reverses lupus-associated immunopathology.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lupus erythematosus (SLE) can affect a plethora of organ systems and cause organ damage due to the disease process and medication toxicity, notably corticosteroids. Patients with SLE often suffer irreversible organ damage. Older age, glucocorticoid use, longer disease duration, and disease activity all represent risk factors for organ damage. This study aims to assess the incidence and predictors of organ damage among Saudi Arabian SLE patients. Methods: This study is a single-center, retrospective cohort observational study conducted at the adult Rheumatology Outpatient Clinic in King Fahad Medical City, Riyadh, Saudi Arabia. It included all patients aged 16 years and older who met at least four of the American College of Rheumatology Classification criteria for SLE or had a renal biopsy consistent with lupus nephritis and had regular follow-ups at our hospital, with the last visit occurring within 2 years. Results: The study included 196 patients with SLE, predominantly female (92.9%) with a mean age of 36.2 years and an average disease duration of 8.88 years. Among the patients, 38.8% had a positive Systemic Damage Index (SDI) score. Hydroxychloroquine was used by 93.4% of the patients, and 46.9% had a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 3 or higher. The neuropsychiatric system was most affected, with 16.8% of patients having positive SDI scores in this domain, followed by the renal system at 9.2%. Patients with positive SDI scores were significantly older, had longer disease duration, and had higher prevalence of diabetes mellitus and hypertension. Conclusion: To address organ damage in SLE patients, integrating adjunctive therapies like antihypertensives and antidiabetic agents into management plans is essential. Future research should adopt prospective cohort designs to evaluate the dynamic interactions between comorbidities and organ damage over time. Additionally, studies should assess the effectiveness of combined treatment strategies and develop targeted approaches for high-risk groups to enhance outcomes and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.